Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$102.97 USD

102.97
668,578

-0.19 (-0.18%)

Updated Sep 24, 2025 04:00 PM ET

After-Market: $102.99 +0.02 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (104 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Catalent (CTLT) Preliminary Q1 Revenues Dampened by Lower Sales

by Zacks Equity Research

Catalent (CTLT) records lower revenues in Biologics segments in its first-quarter fiscal 2024, resulting in overall soft preliminary performance.

Zacks Equity Research

ITGR or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

Alcon (ALC) Q3 Earnings Miss Estimates, Margins Increase

by Zacks Equity Research

Alcon (ALC) Q3 revenues increase year over year, driven by strength in Surgical and Vision Care segments.

Zacks Equity Research

Avantor's (AVTR) New Offerings to Aid Cell and Gene Therapy Suite

by Zacks Equity Research

Avantor's (AVTR) latest offerings are likely to provide its customers with products, materials and services that would aid in accelerating therapeutics.

Zacks Equity Research

Here's Why You Should Retain Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about Penumbra (PEN) on strong vascular and neuro businesses growth and upbeat guidance.

Zacks Equity Research

Bio-Rad (BIO) Hurt by Macroeconomic Woes, Margin Pressure

by Zacks Equity Research

Bio-Rad's (BIO) margin performance is affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.

Zacks Equity Research

Charles River (CRL) to Advance AI Drug Discovery With New Pact

by Zacks Equity Research

Charles River's (CRL) recent partnership will enable the optimization of the discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.

Zacks Equity Research

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health's (CVS) strength in Health Care Benefits business arm and stable solvency position.

Zacks Equity Research

Quest Diagnostics (DGX) Introduces Mobile Phlebotomy Service

by Zacks Equity Research

Quest Diagnostics (DGX) can offer patients and physicians a seamless connection to Quest Diagnostic's laboratory testing with the launch of Quest Mobile.

Zacks Equity Research

Veradigm's (MDRX) New Offering to Enhance Patient Engagement

by Zacks Equity Research

Veradigm's (MDRX) latest solution is likely to offer its clients the right payment option to each individual patient through the right communication channel.

Zacks Equity Research

Hologic's (HOLX) Q4 Earnings Beat Estimates, Gross Margin Down

by Zacks Equity Research

Solid year-over-year growth in the Breast Health segment drives Hologic's (HOLX) Q4 performance.

Zacks Equity Research

Zacks.com featured highlights Oshkosh, Everest Group, Leidos, Itron and Integer

by Zacks Equity Research

Oshkosh, Everest Group, Leidos, Itron and Integer have been highlighted in this Screen of The Week article.

Zacks Equity Research

BD (BDX) Q4 Earnings In-Line With Estimates, Margins Contract

by Zacks Equity Research

BD's (BDX) overall top line benefits from revenue growth in all its segments and both geographic regions in the fiscal fourth quarter.

Zacks Equity Research

Here's Why You Should Retain Boston Scientific (BSX) Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX), led by growing demand for WATCHMAN FLX devices and upbeat guidance.

Zacks Equity Research

Alcon (ALC) Unveils New Progress in Presbyopia Correcting IOLs

by Zacks Equity Research

Alcon's (ALC) Clareon Vivity IOL highlights proven results and high levels of patient satisfaction. It will offer a similar halo profile compared with a monofocal IOL.

Zacks Equity Research

Surmodics (SRDX) Q4 Earnings Top Estimates, Revenues Up Y/Y

by Zacks Equity Research

Surmodics (SRDX) reports a solid fiscal fourth quarter top line on the back of robust segmental revenues.

Zacks Equity Research

Inspire Medical (INSP) Q3 Earnings Top Estimates, Revenues Lag

by Zacks Equity Research

Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the third quarter.

Urmimala Biswas headshot

5 Attractive PEG-Based GARP Stocks for Investors

by Urmimala Biswas

Here are the five stocks that meet our screening criteria ¿¿¿ OSK, EG, LDOS, ITRI and ITGR.

Zacks Equity Research

Inogen (INGN) Q3 Earnings Miss Estimates, Revenues Down Y/Y

by Zacks Equity Research

Despite higher international business-to-business sales and rental revenues, Inogen's (INGN) overall third-quarter results reflect soft performances.

Zacks Equity Research

Accuray (ARAY) Q1 Earnings In-Line With Estimates, Revenues Top

by Zacks Equity Research

Accuray (ARAY) reports a solid fiscal first quarter top line on the back of robust Product revenues.

Zacks Equity Research

Charles River's (CRL) Q3 Earnings Beat, Margins Decline

by Zacks Equity Research

Charles River's (CRL) RMS organic revenue growth is primarily driven by research model services, particularly the Insourcing Solutions business.

Zacks Equity Research

DaVita (DVA) Q3 Earnings & Revenues Top Estimates, Margins Up

by Zacks Equity Research

DaVita's (DVA) robust segmental revenues drive its third-quarter performance.

Zacks Equity Research

Masimo (MASI) Q3 Earnings Beat Estimates, Margins Fall

by Zacks Equity Research

Masimo's (MASI) overall third-quarter results reflect soft performance despite strength in the Hearables category.

Zacks Equity Research

Globus Medical (GMED) Q3 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Globus Medical's (GMED) legacy business continues to drive share growth across its U.S. spine and trauma portfolios in the third quarter.

Zacks Equity Research

Here's Why You Should Retain Align Technology (ALGN) Stock Now

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN), led by its strong global presence.